Conmed Corp Stock Price, News & Analysis

CONMED Corporation (NYSE: CNMD) has scheduled its second quarter 2025 financial results announcement for July 30, 2025, after market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results.

Investors can participate in the conference call via telephone by pre-registering to obtain dial-in details. Additionally, a webcast will be available through the "Investors" section of CONMED's website, with a replay accessible approximately one hour after the call concludes.

CONMED Corporation (NYSE: CNMD) has announced the appointment of LaVerne Council as the new Independent Chair of its Board of Directors, effective May 21, 2025. Council will succeed Martha Goldberg Aronson, who will continue to serve as a Director. The change reflects CONMED's commitment to periodic Board and Committee Chair rotations.

Council, recognized for her global operations and information technology expertise, expressed commitment to working with the Board and leadership team to execute the company's long-term strategy. The company aims to empower healthcare providers, deliver stockholder returns, create an engaging employee environment, and drive business success.

CONMED Corporation (NYSE: CNMD) has announced a quarterly cash dividend payment. The company's Board of Directors has declared a dividend of $0.20 per share. The dividend was declared on May 20, 2025, and will be paid on July 3, 2025 to shareholders who are on record as of June 13, 2025.

CONMED Corporation reported Q1 2025 financial results with sales of $321.3 million, showing a 2.9% year-over-year increase. The company saw domestic revenue growth of 4.2% and international revenue growth of 1.2% (3.4% in constant currency).

Key financial metrics include:

• GAAP diluted earnings per share dropped to $0.19 from $0.63 in Q1 2024
• Adjusted diluted earnings rose to $0.95 from $0.79 year-over-year
• Gross profit margin improved to 55.3% from 55.1%

The company updated its 2025 outlook, now expecting full-year revenue between $1.350-1.378 billion and adjusted EPS of $4.45-4.60. However, recent tariff announcements could impact EPS by approximately $0.14 in H2 2025. The company noted reduced currency headwinds of 50-70 basis points, down from previous estimates of 100-120 basis points.

CONMED (NYSE: CNMD) has scheduled its first quarter 2025 financial results announcement for April 30, 2025, after market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the quarterly performance. Interested participants can pre-register to obtain dial-in details and passcode. The call will also be available via webcast through CONMED's investor relations website, with a replay accessible approximately one hour after the call conclusion.

CONMED (NYSE: CNMD) announced that Mark Kaye will join its Board of Directors effective February 24th, 2025. Kaye brings extensive experience in finance, accounting, risk management, strategic planning, and operational efficiencies, along with expertise in corporate governance and healthcare.

Kaye currently serves as Executive Vice President and Chief Financial Officer of Elevance Health since 2023. His previous roles include EVP and CFO at Moody's (2021-2023), SVP-CFO at Moody's (2018-2021), and leadership positions at MassMutual and Voya Financial. He has served as a Director on the Board of BCS Financial since 2024.

Both Martha Goldberg Aronson, Chair of CONMED's Board, and Patrick Beyer, President and CEO, expressed enthusiasm about Kaye's addition, highlighting how his healthcare and financial expertise will help guide CONMED's growth opportunities to benefit customers, shareholders, and employees.

CONMED (NYSE: CNMD) has announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share. The dividend was declared on February 24, 2025, and will be payable on April 4, 2025.

This payment will be distributed to all shareholders who are on record as of March 14, 2025. The announcement was made from CONMED's location in Largo, Florida.

CONMED (NYSE: CNMD) reported its Q4 and full-year 2024 financial results. In Q4, sales reached $345.9 million, up 5.8% year-over-year, with domestic revenue increasing 6.8% and international revenue growing 4.4%. Q4 GAAP earnings per share were $1.08, while adjusted EPS reached $1.34, up 26.4% from Q4 2023.

For full-year 2024, sales totaled $1,307.0 million, a 5.0% increase, with domestic revenue up 6.9% and international revenue rising 2.6%. Full-year GAAP EPS was $4.25, with adjusted EPS at $4.17, up 20.9% from 2023.

Looking ahead to 2025, CONMED projects revenue between $1.344-1.372 billion, representing 4-6% constant currency growth, and adjusted EPS of $4.25-$4.40, factoring in currency headwinds but excluding potential tariff impacts.

CONMED (NYSE: CNMD) has announced it will release its fourth quarter 2024 financial results after market close on Wednesday, February 5, 2025. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results. Interested parties can pre-register for the telephone conference, and a webcast will be available through the Investors section of CONMED's website. A replay of the webcast will be accessible approximately one hour after the call concludes.